Regulacje i polityka gospodarcza · 19/12/1995

Cochlear Corp. Receives FDA Approval for New Indication for Use of Nucleus 22-Channel Cochlear Implant

The US Food and Drug Administration (FDA) has approved Cochlear Corp.'s supplemental application for premarket approval of a new indication for use of the Nucleus 22-Channel Cochlear Implant, following a notification by the FDA's Center for Devices and Radiological Health (CDRH) on August 21, 1995.